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SUMMARY
Aims: Substantial evidence indicates that 5-HT2C receptors are involved in the control of
neuronal network excitability and in seizure pathophysiology. Here, we have addressed the
relatively unexplored relationship between temporal lobe epilepsy (TLE), the most frequent
type of intractable epilepsy, and 5-HT2CRs. Methods: In this study, we investigated this
issue using a model of partial complex (limbic) seizures in urethane-anesthetized rat, based
on the phenomenon of maximal dentate activation (MDA) using 5-HT2C compounds, elec-
trophysiology, immunohistochemistry, and western blotting techniques. Results: The
5-HT2C agonists mCPP (1 mg/kg, i.p) and lorcaserin (3 mg/kg, i.p), but not RO60-0175 (1–
3 mg/kg i.p.), were antiepileptogenic reducing the MDA response duration. The selective
5-HT2C antagonist SB242084 (2 mg/kg, i.p) unveiled antiepileptogenic effects of RO60-
0175 (3 mg/kg, i.p) but did not alter those induced by mCPP and lorcaserin. Compared with
control rats, electrically stimulated rats showed an increase in glutamic acid decarboxylase
levels and a heterogeneous decrease in 5-HT2CR immunoreactivity in different hippocampal
areas. Conclusions: In our animal model of TLE, mCPP and lorcaserin were anticonvul-
sant; likely acting on receptor subtypes other than 5-HT2C. Epileptogenesis induced early
adaptive changes and reorganization in the 5-HT2CR and GABA systems.
Introduction
The serotonin (5-hydroxytryptamine; 5-HT) 2C receptor (5-HT2CR)
subtype is one of the most studied members of the serotonin
receptor family that holds up to 14 subtypes [1–4]. This is not
surprising, considering that it is widely expressed within the
central nervous system (CNS) and is thought to play a major
role in 5-HT regulation of a plethora of behaviors. Despite the
importance of the 5-HT2CR, our understanding of its complex
signal transduction properties remains incomplete. This is due
to its distinctive regulatory properties, such as constitutive
activity and RNA-editing in vivo and especially the scarcity of
subtype-selective drugs [5,6]. Nevertheless, 5-HT2CR has been
shown by experimental and clinical observation to represent a
possible therapeutic target for the development of drugs for a
range of CNS disorders such as schizophrenia, depression, drug
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abuse, eating disorders, and Parkinson’s disease to name but a
few [1,5–7]. As activation of 5-HT2CRs suppresses neural net-
work hyperexcitability in different brain areas [7–9], it might
play a similar role in the hippocampus. This hypothesis is cor-
roborated by the high 5-HT2CR mRNA and protein hippocam-
pal expression [10,11] with immunoreactivity for the 5-HT2CR,
wildly located in the polymorphic cell layer of the dentate
gyrus (DG), in the pyramidal cell layer of hippocampus proper
(CA1, CA2, and CA3 fields), in the mossy fibers of CA3 and in
the subiculum [12,13]. Moreover, 5-HT2C knock out (KO) mice
show a selective impairment of DG plasticity in vitro, spatial
learning impairment and emergence neophobia [14]. Consis-
tently, 5-HT2CR activation decreases theta oscillations [15]
implying that 5-HT2CR antagonists might have therapeutic sig-
nificance in psychiatric or neurological disorders associated
with impaired cognitive functions and epilepsy. 5-HT2CR KO
mice are extremely susceptible to audiogenic seizures [16], and
prone to spontaneous death from seizures [17]. Furthermore,
an up-regulation of 5-HT2CRs with an increase in hippocampal
gene expression and inositol triphosphate content and associ-
ated depressive mood behavioral changes have recently been
shown in pilocarpine-induced temporal lobe epilepsy (TLE) in
rats [18].
Despite these compelling data, research on the role of 5-HT2CRs
in TLE, the most frequent type of intractable epilepsy, has been
relatively scarce and lead to conflicting results [8,19].
In this study, we used a model of partial complex (limbic)
seizures based on the phenomenon of maximal dentate
activation (MDA) recorded in the DG, induced by repetitive
electrical stimulation of the perforant path (PP) in anesthetized
rats [20,21]. To answer the question of a possible involvement
of 5-HT2CR in TLE, we evaluated the anticonvulsant properties
of some old and newer 5-HT2CR agonists, that is, mCPP, RO60-
0175, and lorcaserin and the selective 5-HT2CR antagonist SB
242084 using the MDA animal model. Moreover, standard
immunohistochemistry, and western blotting were used with
the aim to elucidate whether any adaptive changes in the 5-
HT2C and GABA systems occurred in early-stage hippocampal
epileptogenesis by evaluating the expression of 5-HT2CR and
GAD67 in the hippocampus of rats that underwent the MDA
protocol compared with the control group.
Materials and Methods
Animals
Male Sprague-Dawley rats (Charles Rivers, IT) weighing
between 250 and 300 g were used. Procedures involving
animals and their care were in accordance with Council
Directive 86/609/EEC and with the Animals Scientific
Procedures Act 1986, and local regulations regarding in animals
in research. Surgery and field potentials recordings were
performed as previously described [20,22]. Briefly, the
population spike (PS) was evoked by stimulating the medial
perforant path (PP) (AP:-8.3 L:4.8 V:3.4; [23]) and recorded
with a bipolar stimulating electrode (bifilar stainless steel wire,
CFW, CA, USA) in the hilus of the DG of the hippocampus
(AP: -4.8 L: 2.2 V: 3.6) (Figure 1A). Electrical activity was
recorded by a NeuroLog amplifier (Digitimer Ltd, high pass:
0.2 Hz, low pass: 5000 Hz, gain: 200). A digitally controlled
constant current stimulator (Digitimer Ltd, model DS3) was
used to apply square-wave pulses of 0.3 ms duration, 1 per
min. PS amplitude was calculated as shown in Figure 1B. Stim-
ulus intensity was set to evoke 45–50% of the maximum
amplitude of the PS. Responses were digitized by a CED 1401
plus analog-digital converter (Cambridge Electronic Design Ltd.,
Cambridge, UK), stored on a computer and averaged offline
using Signal 1.9 software. Sampling rate was set to 10 kHz.
Location of the electrodes was verified histologically (Fig-
ure 1A).
Maximal Dentate Activation
The induction of the MDA was started when normal DG excit-
ability was revealed, 30 min or more following surgery. This
was assessed by paired pulse stimulation with two different
interpulse intervals (i.e., 25 and 150 msec), capable of inducing
fast inhibition and excitation, respectively [20,22]. MDA was
characterized electrophysiologically according to published crite-
ria [20,24]. Stimulus trains of 10 second (pulses of 0.3 ms
duration, at 20 Hz) were delivered through the PP electrode at
an initial intensity of 100 lA. If MDA was not elicited, the
stimulus intensity was increased in 50 lA steps and redelivered
every 2.5 min until MDA was induced. Threshold was reached
at 350  100 lA, and stimulus intensity was further increased
by 100 lA. For each stimulus, the duration of MDA, time to
onset and after discharge (AD) were measured as shown in
Figure 1C.
Repeated trains inducing seizure were delivered every
10 min for 4 h (total of 24 stimulus trains). As shown in Fig-
ure 1D, the latency to MDA onset was measured from stimu-
lus onset to the point of PS appearance with half of the
maximal amplitude [20].
After the AD began to lengthen, either drug or vehicle was
administered after six stimulus train. In the vehicle group, the
duration of MDA increases and the time to onset gradually
decreases [20,21]. To make comparisons across animals, the mea-
sured durations of MDA and time to onset were “normalized” by
subtracting their duration in response to the first stimulus from
the duration in response to each subsequent stimulus train. Thus,
for individual stimulus trains after the first, a change in duration
(or time to onset) was calculated. In this way, data from separate
animals were averaged and comparisons across groups of animals
were made [20,21].
Immunohistochemistry, Western Blot analysis,
and Statistical analysis
See supporting information.
Drug Administration Protocols
The drugs were all administered i.p., and the effect on the
MDA parameters was recorded in a dose volume of 1 ml/kg.
Ro60-0175 (1, 3, and 10 mg/kg), mCPP (1 mg/kg), and lorcas-
erin (3 mg/kg) were dissolved in saline, SB242084 in 20%
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DMSO and saline. Lorcaserin was a gift from Arena pharma-
ceutical; the other compounds were purchased from Sigma-
Aldrich, Gillingham, UK.
Results
Effect of RO60-0175, mCPP, Lorcaserin, and
SB242084 on the Maximal Dentate Activation
Parameters
The effects of the different 5-HT2c/ ligands were compared with
those of their vehicles (saline and 20% DMSO) on MDA duration
and the time to onset of MDA (Figure 1C and 2A). The results
from the vehicle-treated animals were determined on nine ani-
mals (n = 5 for saline and 4 for 20% DMSO) and averaged
together because they were not statistically significant (not
shown) and indicated from now on as control group. Time of
onset gradually decreased over the first eight stimuli
(1.9  4) seconds and then stabilized for the remainder of the
experiment (Figures 1C and 2C). Conversely, MDA increased
steadily, reaching a peak at the 24th stimulus (+24.6  2.4 sec-
onds), although a value fluctuation was observed over the last
stimuli. The lengthening of the MDA duration was significantly
and differently affected by the 5-HT2C compounds used in this
study (Figures 2–4). Similarly, a pattern of effects was seen for the
AD (data not shown).
Effect of RO60-0175 on MDA Parameters and
Role of 5-HT2C Receptors
The effect of RO60-0175 (1, 3 and 10 mg/kg, i.p) on the magni-
tude of MDA elongation is reported in Figure 2A. Despite a trend
toward a decrease after 1 or 3 mg/kg, RO60-0175 did not signifi-
cantly alter the duration of MDA (one-way ANOVA, F3,22 =
0.711; P = 0.556) (Figure 2A).
Figure 2B reports the effect of the 5-HT2C antagonist SB242084
(2 mg/kg i.p.) on MDA responses obtained in the presence or the
absence of RO60-0175 (3 mg/kg i.p.).
Statistical analysis revealed a significant reduction of the
MDA elongation by cotreatment with SB242084 (2 mg/kg, i.p.)
and RO60-0175 (3 mg/kg) (one-way ANOVA, F3,23 = 3.418;
P = 0.0342). However, SB242084 was without effect by itself (SB
vs. control, Fisher PLSD test, P = 0.5585; n = 5) (Figure 2B). The
inhibitory effect produced by this combination was observed as
early as frame 10 (Figure 2B; n = 7).
Despite a trend toward inhibition, RO60-0175 (1, 3, 10 mg/kg
n = 6) did not alter the onset of the MDA (one-way ANOVA,
F3,22 = 0.054, P = 0.6552) (Figure 2C). Pre-treatment with the
Figure 1 (A) Stereotaxic coronal plates in
which the recording (above) and the
stimulating (below) electrodes were placed.
The two photomicrographs of 100 lm-thick
coronal sections on the right panels represent
the anatomical location of the electrodes in the
dentate gyrus (DG) and angular bundle
(perforant pathway, PP), respectively. (B)
Representative trace of evoked field potential
recorded in DG in response to stimulation of PP
fibers. The field excitatory postsynaptic
potential (fEPSP) slope is represented by the
maximum slope of the line that best fitted to
seven steepest points of the rising phase of the
local field potential (dashed line). The
population spike (PS) amplitude is measured as
the distance of the vertical line from the
tangent line drawn connecting the first peak
with the second peak of the positive deflection
and the valley of the evoked field potential
(arrow). (C) Measurement of the parameter of
Maximal dentate activation (MDA) in control
animals. The Time to onset is defined by the
time that occurs from the beginning of the
stimulus train to the midpoint of the maximum
amplitude of the PSs. The duration of the MDA
is measured from the time to onset and the
end of the epileptic afterdischarges (AD). AD is
represented by spontaneous bursts of PSs that
appear at the end of the stimulus train.
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selective 5-HT2C antagonist SB242084 (2 mg/kg, i.p, n = 7), with-
out effect by itself (SB vs. control, Fisher’s PLSD test, P = 0.9635),
did not reveal any interaction with 3 mg/kg RO60-0175 on the
time to onset of MDA (Figure 2D). Conversely, RO60-0175 (1, 3,
10 mg/kg, n = 6 for each dose), SB242084 (2 mg/kg, n = 7) and
cotreatment with 3 mg/kg RO60-0175 and SB242084 did not
effected the onset of the MDA (Figure 2C,D).
Effect of mCPP on MDA Parameters and Role of
5-HT2C Receptors
The average effect of mCPP (1 mg/kg i.p.; n = 5) treatment on
MDA elongation is shown on Figure 3A. ANOVA analysis
revealed a dramatic decrease in duration of the MDA induced by
mCPP (one-way ANOVA F3,20 = 5.316, P = 0.0074), nearly block-
ing it 40 min (stimulus 10) after its administration (mCPP vs. con-
trol, 2.7  0.8 vs. 11.1  1.4, Fisher’s PLSD test, P = 0.0017), an
effect which lasted for the entire duration of the experiment with
variable entity. SB pre-treatment tended to potentiate mCPP
(1 mg/kg) effects (mCPP + SB vs. mCPP, Fisher’s PLSD test,
P = 0.5441) (Figure 3B). The effects of mCPP (1 mg/kg i.p.;
n = 5) or its cotreatment with SB242084 (n = 5) did not signifi-
cantly affect the onset of the MDA (one-way ANOVA,
F3,20 = 0.052, P = 0.9837).
Effect of Lorcaserin on MDA Parameters and
Role of 5-HT2C Receptors
As shown in Figure 4A, administration of lorcaserin (3 mg/kg, i.p;
n = 5) produced a significant sustained decrease of the MDA elon-
gation (one-way ANOVA, F3,20 = 4.328, P = 0.0166). Post hoc
analysis revealed that the peak effect was attained at stimulus 10
(LOR vs. control, 7.5  4.0 vs. 11.1  1.4; Fisher’s PLSD test,
P = 0.0389) and sustained for 90 min after. SB pre-treatment
tended to potentiate lorcaserin (3 mg/kg) effects (LOR + SB vs.
LOR, Fisher’s PLSD test, P = 0.5752) (Figure 4A). The effects of
lorcaserin (3 mg/kg i.p.; n = 5) or its cotreatment with SB242084
(LOR + SB, n = 5) did not significantly affect the onset of the
MDA (one-way ANOVA, F3,20 = 0.202, P = 0.8936) (Figure 4B).
Distribution of 5-HT2C Receptor Immunoreactivity
in the Dentate Gyrus, Hippocampus Proper, and
Entorhinal Cortex
Control Rats
General Staining Features
The 5-HT2C immunoreaction product was usually limited to a dark
cell body but was not present in the proximal dendrites. The neu-
Figure 2 Effect of RO60-0175 (RO) on the parameters of the maximal dentate activation (MDA). The duration and time to onset of MDA were measured
for each stimulus train. These values were then normalized, averaged and plotted (SEM) against stimulus number. Drugs were administered i.p. at the
arrows. The open square line indicates the mean values from the vehicle control animals (n = 9). The effect of RO at 1 mg/kg (n = 5, filled squares), 3 mg/
kg (n = 7, filled circles) and 10 mg/kg (n = 6, filled triangles) on the increase in duration of MDA (A) and on the change in the time to onset of MDA (C). The
effect of SB242084 2 mg/kg alone (n = 5, empty circles) or combined with RO 3 mg/kg (n = 7, filled circles), on the increase in duration of MDA (B) and on
the change in the time to onset of MDA (D). One-way ANOVA for repeated measures followed by Fisher’s PLSD post hoc test; *P < 0.05 versus vehicle
group.
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ropil staining consisted only of diffuse staining without any visible
dendrite. The diffuse neuropilar labeling could not be associated
with any specific neuronal elements.
GAD67 immunohistochemistry distributions are described in
the supporting information.
Dentate Gyrus
In the DG, most of the 5-HT2CR-immunoreactive (IR) somata
were located in the granule cell and polymorphic cell layers
(Figure 5A1,B1; Table 1). Virtually, all granule cells were positive
for the 5-HT2CR (Figure 5A1,B1). A low density of 5-HT2CR-IR
neurons was located also in the molecular layer (Table 2). A
strong diffuse neuropilar staining could be observed especially in
the polymorphic cell layers (Figure 5A1,B1; Table 2).
Hippocampus Proper
5-HT2CR immunoreactivity was quite similar in the different fields
of the hippocampus proper (Figure 6A1,B1; Tables 1 and 2). 5-
HT2CR-IR cell bodies were primarily located in the pyramidal cell
layer and, presumably, belong to pyramidal neurons (Figure 6A1,
B1; Table 1). A low density of immunopositive cells could be
observed also in strata oriens, radiatum and lacunosum
moleculare (Figure 6A1,B1; Table 1). The diffuse neuropilar
staining was evident throughout the layers of hippocampus
proper (Figure 6A1,B1; Table 2). However, the stratum lucidum
of the CA3 field (where the mossy fibers are present) showed a
low level of diffuse neuropilar immunoreactivity.
Entorhinal Cortex
A high density of 5-HT2CR-IR somata could be observed in the
entorhinal cortex (Figure 6C1; Table 1). The great majority of
5-HT2CR-IR cell bodies, which probably belonged to pyramidal or
modified pyramidal cells, were located in layers II, III, V, and VI
(Figure 6C1). The diffuse neuropilar staining was high in every
layer (Figure 6C1; Table 2).
MDA-Stimulated Rats
The 5-HT2CR immunostaining was more prominent in control
than in MDA-stimulated rats (Figure 5A1–A2, B1–B2; Fig-
ure 6A1–A2, B1–B2, C1–C2; Tables 1 and 2). Moreover, the
MDA-stimulated left (MDAL) hemisphere, ipsilateral to the PP
stimulation, presented more effects in all the areas examined,
compared with MDA-stimulated right (MDLR) hemisphere and
nonstimulated control brains (Tables 1 and 2). In fact, a diffuse
reduction of the number of immunoreactive somata could be
observed in MDA-stimulated rats (Figure 5A1–A2, B1–B2; Fig-
ure 6A1–A2, B1–B2, C1–C2; Table 1). This aspect was statistically
significant in the granular cell layer, polymorphic cell layer, pyra-
Figure 3 Effect of mCPP and SB242084 (SB)
on the parameters of the maximal dentate
activation (MDA). The duration and time to
onset of MDA were measured for each
stimulus train. These values were then
normalized, averaged and plotted (SEM)
against stimulus number. Drugs were
administered i.p. at the arrows. The dashed
line indicates the mean values from the vehicle
control animals (n = 9). The effect of mCPP at
1 mg/kg (n = 5, filled squares), SB 2 mg/kg
(n = 5, opened circles) and the combined
administration of mCPP and SB (n = 5, filled
circles) on the change in duration of MDA (A)
and on the change in the time to onset of MDA
(B). One-way ANOVA for repeated measures
followed by Fisher’s PLSD post hoc test;
*P < 0.05 versus vehicle group; **P < 0.01
versus vehicle group.
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midal cell layer, and entorhinal cortex (Table 1). In addition, the
intensity of neuronal immunostaining was less evident in MDA-
stimulated rats than in control rats. In every region analyzed, the
intensity of diffuse neuropilar immunostaining was highest in
control rats than in MDA-stimulated ones (Figure 5A1–A2, B1–
B2; Figure 6A1–A2, B1–B2, C1–C2; Table 2).
Effects of MDA on 5-HT2C and GAD67 Expression
Levels in the Hippocampus Measured by
Western Blotting
The expression levels of 5-HT2CR and GAD67 were investigated in
protein lysates of hippocampus derived from control and
Figure 4 Effect of lorcaserin (LOR) and
SB242084 (SB) on the parameters of the
maximal dentate activation (MDA). The
duration and time to onset of MDA were
measured for each stimulus train. These values
were then normalized, averaged and plotted
(SEM) against stimulus number. Drugs were
administered i.p. at the arrows. The dashed
line indicates the mean values from the vehicle
control animals (n = 9). The effect of LOR at
3 mg/kg (n = 5, filled squares), SB 2 mg/kg
(n = 5, opened circles) and the combined
administration of LOR and SB (n = 5, filled
circles) on the change in duration of MDA (A)
and on the change in the time to onset of MDA
(B). One-way ANOVA for repeated measures
followed by Fisher’s PLSD post hoc test;
*P < 0.05 versus vehicle group; **P < 0.01
versus vehicle group.
Figure 5 Distribution of 5-HT2C receptor
(5-HT2CR) immunoreactivity in the dentate
gyrus (DG) of control (A1, B1) and MDA-
stimulated rats (A2, B2). (A1–A2) Granule cells
are more numerous in control than in MDA-
stimulated rats. Also the intensity of diffuse
neuropilar immunostaining is higher in the
control than in MDA-stimulated rats. (B1–B2)
Polymorphic cell layer. The number of
immunostained neurons, as well as the
intensity of diffuse neuropilar staining, are
more evident in the control than MDA-
stimulated rats. Scale bar = 200 lm in A1
(applies to A1, A2); 50 lm in B1 (applies to B1,
B2). GL, granule cell layer; ML, molecular layer;
PL, polymorphic cell layer.
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MDA-stimulated rats. 5-HT2C and GAD67 expression levels were
normalized for beta actin expression levels. Western blotting
analysis for 5-HT2C did not show any significant differences within
the groups (Figure 7A,B; P > 0.05), while the levels of GAD67
were significantly increased (P < 0.05, Figures 7C and 3D) in the
MDAR hippocampus compared to MDAL and control rat hippo-
campi. GAD67 immunohistochemistry analysis are described in
the supporting information.
Discussion
In the present study, we report an important impact of the rat
MDA model of hippocampal seizures on the distribution of
5-HT2CR in the hippocampal regions without changes of its total
expression. Surprisingly, although mCPP and lorcaserin behaved
as antiepileptogenic agents, their effects were not blocked by
selective 5-HT2C SB242084 antagonist. Therefore, it seems that
5-HT2CRs do not control the electrophysiological features of the
TLE model used here. Our data suggest that 5-HT2CR could be
linked to TLE via an anatomo-functional reorganization of GAB-
Aergic transmission in the hippocampus during epileptogenis
rather than influence directly paroxysmal discharges of the DG
granular cells.
Our results are in line with data stressing the important role of
5-HT transmission in regulating hippocampal excitability and sei-
zure activity [19] but dampen the idea that 5-HT2CR play a role in
this activity. Thus, to our knowledge, the present electrophysio-
logical study is the first in vivo investigation of the effects of acute
treatment of a number of agonists with different chemical struc-
tures, different affinity and selectivity over the different 5-HT2
subtypes [2] namely mCPP [25,26], lorcaserin [27] and RO60-
0175 [28] and the 5-HT2C antagonist SB242084 [29] on the DG
Table 2 Density of 5-HT2CR dendrites-immunoreactive and intensity of the diffuse neuropilar staining in control and MDA rats
Area Layer
Control MDA
Dendrites Diffuse staining Dendrites Diffuse staining
Dentate Gyrus Polymorphic cell layer  +++  +(L)/++(R)
Granule cell layer    
Molecular layer  ++  +
Hippocampus proper
CA1 Stratum oriens  ++/+++  +
Pyramidal cell layer    
Stratum radiatum  ++/+++  +
Stratum lacunosum-moleculare  ++/+++  +
CA3 Stratum oriens  ++/+++  +
Pyramidal cell layer    
Stratum radiatum  ++/+++  +
Stratum lacunosum-moleculare  ++/+++  +
Entorhinal cortex  ++/+++  +
The density of dendrites and the intensity of the diffuse neuropilar staining is expressed as + + + high, + + medium, + low,  absent. L: left; R: right.
Table 1 The density of 5-HT2C receptor-immunoreactive neurons in control and right and left hippocampal formation/entorhinal cortex of MDA-
stimulated rats
Area Layer Control (n = 3) MDAL (n = 3) MDAR (n = 3)
Dentate Gyrus Polymorphic cell layer* 355  36.5 105.9  18.2* 103.1  18.3*
Granule cell layer* 8537  151 1853  121* 1332  98.9*,#
Molecular layer 72.5  13.6 48.3  14.1 44.1  14.8
Hippocampus proper
CA1 Stratum oriens 127  18.9 46.4  6.3 44.2  5.9
Pyramidal cell layer 5661  123 3812  115.9* 3581  114*
Stratum radiatum 15.1  5.1 13.1  4.5 10.0  4.1
Stratum lacunosum-moleculare 70.1  15.9 57.1  16.4 55.1  16.1
CA3 Stratum oriens 89.4  15.8 61.7  14.3 57.3  12.8
Pyramidal cell layer 2366  98.6 1447  89.1* 1404  87.5*
Stratum radiatum 33.2  9.6 46.4  13.3 44.1  12.1
Stratum lacunosum-moleculare 65.7  13.9 62.5  13.4 58.1  11.1
Entorhinal cortex 561  41.7 297  27.3* 289  23.1*
The density of 5-HT2C receptor-immunoreactive neurons is expressed as the mean/mm
2; n = number of rats in each group. *P < 0.05 MDAL and
MDAR versus control. #P < 0.05 MDAL versus MDAR. MDAR: right hippocampus of MDA-stimulated rats. MDAL: left hippocampus of MDA-stimulated
rats.
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granular cell hyperexcitability. It is interesting to note that RO60-
0175 was devoid of any significant antiepileptic effects over a wide
range of doses (1–10 mg/kg). This regimen has been previously
shown to be efficient on various electrophysiological, biochemical,
and behavioral experiments [30–35] strongly suggesting that 5-
HT2CR stimulation is not involved in the control of MDA elonga-
tion. The presence of the 5-HT2C antagonist SB242084 unmasked
a decrease in MDA response highlighting the antiepileptic proper-
ties of RO60-0175. Interestingly, mCPP and lorcaserin signifi-
cantly reduced the MDA elongation over the 4-h period of
recording. Their effects, not blocked by the pretreatment with
SB242084, tended instead to be potentiated by the antagonist.
The mere involvement of 5-HT2CR in the electrophysiological
feature of MDA has been also confirmed on the time to onset of
MDA. The latency to onset of MDA can be used as a gauge of sei-
zure threshold (anticonvulsant) and the duration of MDA as a
measure of processes that terminate seizure activity in the limbic
system and its decrease has been considered to be antiepileptogen-
ic [36]. The anticonvulsant and the antiepileptogenic processes
likely involve different mechanisms [37] and in accordance none
of the agonists significantly affected the onset of the MDA, while
mCPP and lorcaserin strongly decreased the MDA-associated after
discharges elongation.
Overall, these data suggest that MDA does not respond to phasic
stimulation of 5-HT2CR. Moreover, our data show also that MDA
response is under a poor tonic influence exerted by 5-HT2CR.
Indeed, the selective 5-HT2CR antagonist SB242084 (2 mg/kg,
i.p.) did not induce any proconvulsant effects seen such as
elongation of the MDA and AD in rats or reduction of the MDA
latency. Thus, in contrast to the situation reported in 5-HT2C KO
mice [17], the lack of a 5-HT2CR tonic control on epilepsy is in
agreement with data from generalized epilepsy models [19]. It has
been previously reported that SB242084 or the other selective
antagonist SB243213 were unable to reduce seizure threshold in
adult rodents [8]. Although a constitutive activity of 5-HT2CR
could have hardly been unmasked with SB242084 [38], previous
data have reported that the prototypical inverse agonist SB206553
did not alter on its own seizure threshold [39]. Thus, it appears
that endogenous 5-HT2CR tone exerts a poor influence on the
general activity.
The nonselective and distinct effects triggered by the agonists
used in this study deserve comments. It is possible that the differ-
ent effects of the agonists are related to their different affinity to
5-HT2AR [2]. Another possible candidate for the antiepileptic
effects is the 5-HT1AR, for which among all the 5-HTRs the most
compelling evidence exists for a causative role in TLE [40]. Consis-
tently, we recently showed, using the same experimental
approach, that 8-OH-DPAT decreased the MDA elongation in a
similar way to mCPP and lorcaserin [20]. Moreover, mCPP [26],
lorcaserin [41] and RO60-0175 [28] bind 5-HT1ARs. The loss of
selectivity of mCPP and RO60-0175 has already been reported in
the literature at these regimens. Indeed, 1 mg/kg mCPP has been
shown to enhance c-fos expression in the striatum or alter loco-
motor activity in part via mechanisms involving 5-HTR other than
Figure 6 Distribution of 5-HT2C receptor
(5-HT2CR) immunoreactivity in the
hippocampus proper and entorhinal cortex of
control (A1, B1, C1) and MDA-stimulated rats
(A2, B2, C2). (A1–A2) CA1 and (B1–B2) CA3
fields. In the pyramidal cell layer, the density of
immunoreactive pyramidal neurons is lower in
MDA-stimulated rats than in control rats. Also
the density of the 5-HT2CR-IR diffuse neuropilar
staining is low in MDA-stimulated rats than in
control rats. (C1–C2) Entorhinal cortex. Note
that in the MDA-stimulated rats the number of
immunopositive somata, as well as the diffuse
neuropilar immunostaining, are lower than in
control rats. Scale bar = 100 lm in A1 (applies
to A1–B2); 200 lm in C1 (applies to C1, C2).
Abbreviations: PL, pyramidal cell layer; SLM,
stratum lacunosum-moleculare; SO, stratum
oriens; SR, stratum radiatum.
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5-HT2CR [42–44]. Similarly, 5 mg/kg RO60-0175 stimulates
adrenocorticotrophic hormone, oxytocin, prolactin secretion, and
c-Fos expression in basal ganglia by mechanisms independent of
the activation 5-HT2CRs or 5-HT2ARs [45]. Also, the effect of
3 mg/kg RO60-0175 on c-Fos expression in basal ganglia is not
totally reversed by the 5-HT2C antagonist SB243213 [44].
While we are unable to indicate a clear pro- or antiepileptogenic
influence of 5-HT2CR, it has been reported that agomelatine, a 5-
HT2CR antagonist and potent MT1 and MT2 melatonin receptor
agonist, showed anticonvulsant activity in limbic pilocarpine-
induced seizure models [46]. Moreover, 5-HT2C agonists and
antagonists potentiated [47] or inhibited cocaine-induced convul-
sions [48], respectively. Thus, the lack of involvement of 5-HT2CR
in our model does not exclude their participation in other TLE
models or in humans. Moreover, our findings must be interpreted
with caution because they have been obtained under urethane
anesthesia, which is known to alter neuronal, including DG gran-
ular cell [49], excitability. Nevertheless, for consistency with
available data, we selected urethane as the most suitable anes-
thetic for our experiments as all the studies investigating the effect
of drugs on MDA have been carried out under this type of anes-
thesia [20,21,24,50–52].
Although our electrical stimulation protocol is only 4 hours-
long, we have detected 5-HT2CRs and GAD67 expression changes
(see also supporting information). Indeed, an increase in GAD67
and a decrease in 5-HT2CRs immunoreactivity were observed in
the hippocampus of rats that underwent the electrical stimulation
paradigm when compared to nonstimulated rats.
In control subjects, 5-HT2CR-IR was located in the cell bodies of
the granules of the DG, and pyramidal neurons of the CA3 and
CA1 fields of the hippocampus proper and also in the soma of
GABA interneurons in line with previous evidence [10,11,53].
Regarding GAD67, there was no difference in the distribution of
the immunoreactivity among the control and stimulated rat, but
in PP-stimulated rats, GAD67-IR around the CA3 pyramidal neu-
rons and in the polymorphic layer appears much more intense
(see supporting information). WB analysis showed an increase of
GAD67 protein expression in the MDAR hippocampus.
This is an important demonstration that adaptive changes,
namely up-regulation of the GABA system, can occur at an early
stage of epileptogenesis. In the animals which underwent the
MDA stimulation protocol, 5-HT2CR-IR was present at much
lower levels, although the WB did not reveal any change in total
protein in the whole hippocampus. These changes may be com-
pensatory, with the aim of preventing excessive firing of the hip-
pocampal principal cells and development of spontaneous
recurrent seizures. In contrast, a previous study reported hippo-
campal 5-HT2CR up-regulation 2 weeks after the administration
of pilocarpine in rats [18]. These differences can be explained by
the different TLE models used, although it might be possible that
the chronic 5-HT2CR hyperfunction is preceded by an early 5-
HT2CR down-regulation. Further work is required to establish this
possibility.
Our results suggest subtle changes and possible reorganization
of the hippocampal neural network. These findings are particu-
larly interesting, especially in consideration of the fact adaptive
changes are typically visible only after a latent period (1–4 weeks)
from the epileptic insult [37,54]. Our data confirm that the gener-
ation of seizures in the hippocampal-parahippocampal circuits
produces structural alterations and/or adaptations [52,55,56] and
show for the first time that these can be seen earlier (4 h) at the
level of neurotransmission.
It is very difficult to predict the exact brain area in which
these 5-HT2C compounds elicit their antiepileptic effect. The sys-
temic drug application route used here does not allow us to rule
out the involvement of serotonergic mechanisms in extra-hip-
pocampal areas known to be under a 5-HT2A/2C control, such as
mesencephalic dopaminergic areas [57]. In addition, 5-HT2Rs
are both expressed in principal and GABAergic interneurons in
the hippocampus ([53] and present observations) as well as in
other nuclei, increasing the level of complexity of a general
activation. For instance, 5-HT can act on receptors of the 5-HT2
subtype family to depolarize and excite GABAergic interneurons
of the CA1 region [58]. Detailed studies employing local drug
application and antagonists for different 5-HT subtypes are
required to characterize the precise targets of the putative 5-
HT2C ligands in mediating their antiepileptic influences on hip-
pocampal hyperexcitability.
In conclusion, the MDA model of TLE used here allowed us to
propose that TLE may profoundly alter the expression of 5-HT2CR
and increase GABA neurotransmission. The reorganization of 5-
HT2CR after MDA might be an important factor modifying the
Figure 7 5-HT2C and GAD67 expression in the hippocampus of control
and MDA-stimulated rats. (A) Representative western blot bands for 5-
HT2CRs in control (Con), right hippocampus of MDA-stimulated rats
(MDAR) and left hippocampus of MDA-stimulated rats (MDAL). b-actin was
used as an internal control. (B) Relative expression of 5-HT2C. Optical
density of 5-HT2C protein expression is shown as the expression level of 5-
HT2C divided by the expression level of b-actin, as the mean  SD. (C)
Representative western blot bands for GAD67 in Con, MDAR and MDAL.
b-actin was used as internal control. (D) Relative expression of GAD67.
Optical density of GAD67 protein expression is shown as the expression
level of GAD67 divided by the expression level of b-actin, as the
mean  SD. One-way ANOVA for repeated measures followed by
Bonferroni post hoc test; *P < 0.05 versus vehicle group.
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impact of other 5-HTR in the control of tissue excitability as previ-
ously suggested [18,42]. Indeed, we show for the first time a
strong anticonvulsant effects and/or antiepileptogenic activity
induced by lorcaserin and mCPP that are not mediated by 5-
HT2CRs at least in this model of TLE. Further studies are warranted
to further explore lorcaserin antiepileptic activity in various ani-
mal models of TLE, especially in consideration of its availability on
the market for the treatment of obesity. Revealing the exact
mechanism of 5-HT2R ligands may help to discover new potential
drug targets for this form of epilepsy.
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